NCT04821726进行中（未招募）不适用
Evaluation of the Safety and Efficacy of Drug Eluting Balloon Catheter for the Treatment of Patients With Symptomatic Intracranial Atherosclerosis Stenosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 155
- 试验地点
- 1
- 主要终点
- Restenosis
研究概览
简要总结
A prospective, multi-center, single-arm study to evaluate the safety and efficacy of drug eluting balloon catheter for the treatment of patients with symptomatic intracranial atherosclerotic stenosis.
详细描述
This is a prospective, multi-center, single-arm study to evaluate the safety and efficacy of drug eluting balloon catheter (Vmoky) produced by Yinyi (Liaoning) Biotech Co., Ltd. for the treatment of patients with symptomatic intracranial atherosclerotic stenosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 80 years old；
- •Symptomatic intracranial artery stenosis, the degree of intracranial diseased artery vascular stenosis measured under cerebral angiography between 70~99% (WASID method)；
- •Symptoms are still recurrent after conservative medication (symptoms refer to stroke and transient ischemic episodes of the brain)，or intracranial artery stenosis combined with remote low perfusion performance (rCBF or rCBV abnormalities) in patients.
- •The stenotic vessels are located in the internal carotid artery (intracranial segment), middle cerebral artery, vertebral artery (intracranial segment), basilar artery, distal blood vessels are normal；
- •Only one lesion needed to be treated；
- •The intracranial artery needed to be treated l art mm in diameter；
- •Pre-expansion must be satisfied: forward blood flow TICI 3 level, pre-expanded guide wire retention, observation for 5 minutes, residual stenosis is still ≤50%; without blood limited dissection；
- •Patients have at least 1 porridge plaque risk factor, including past or existing hypertension, diabetes, hyperlipidemia, smoking;
- •mRS≤3 points；
- •Patients or their guardians are able to understand the purpose of the trial, voluntarily participate in and sign a written informed consent form, and receive follow-up visits from patients.
排除标准
- •Target lesion is in-stent restenosis；
- •Exist lesion stenosis more than 50% out of the target vessel；
- •Intracranial haemorrhage occurred within 3 months (substantial cerebral hemorrhage, large amount of subcranial hemorrhage, subdural/external bleeding)；
- •Acute ischemic stroke has occurred in the last two weeks；
- •Stenosis caused by non-atherosclerosis: e.g. arterial mezzanine, moya-moya disease, vasculitis, radioactive vascular disease or fibrous muscle dysplasia;
- •Severe calcified, angulate and Mori type C lesions, as well as congenital development of thin blood vessels and fenestration；
- •Combine intracranial tumors, aneurysms, or intracranial venous malformations；
- •There are risk factors that can lead to cardiogenic embolism: fibrillation, left-ventricle thrombosis, mycardial infarction within 6 weeks, etc；
- •Uncontrollable hypertension by medication (Systolic pressure≥ystolic pres diastolic blood pressure≥pressurec；
- •Severe combined or unstable conditions, such as severe heart failure, lung failure or kidney failure (serum creatinine>3.0mg/dL (264 μmol/L) or renal cyspheric filtration rate (GFR) <30ml/min), severe liver insequencies, malignant tumors;
- •A history of gastrointestinal haemorrhage or haemorrhagic disease (e.g. idiopathic platelet reduction cyanosis, etc.) or a history of bleeding tendencies within 6 months prior to the signing of the informed consent；
- •Hemoglobin is below 90g/L, plateplates<90×109/L；
- •The International Standardized Rate (INR) >1.5, with unreal corrective bleeding factors；
- •Can not carry out antiplatelet/anticoagulant treatment, with anaesthetic and contrast agent contraindication;
- •The angiography shows that the vascular path is curly, and the device is difficult to reach the target position or to withdraw；
- •Patients known to be allergic to heparin, paclitaxel, contrast, aspirin and clopidogrel, anesthetics;
- •Life expectancy is less than 1 year；
- •Participants in other drug or device clinical trials that have not been completed；
- •A pregnant or lactating woman, or a person planning to become pregnant within one year；
- •Other conditions that the researchers consider patients are not suitable.
结局指标
主要结局
Restenosis
时间窗: 6 months (+60 days)
Restenosis was defined as greater than 50% stenosis within or immediately adjacent (within 5 mm) to the implanted balloon(s) or stent(s) and greater than 20% absolute luminal loss.
次要结局
- The success rate of device(immediately after procedure)
- Target lesion stenosis(6 months (+60 days) and 12 months (±60 days))
- Restenosis(12 months (±60 days))
- Ischemic stroke and transient ischemic attack (TIA) out of the area of the responsible blood vessels(30 days (±7 days), 6 months (±60 days), 12 months (±60 days))
- Stroke events(30 days (±7 days), 6 months (±60 days) and 12 months (±60 days))
- Ischemic stroke and transient ischemic attack (TIA) in the area of the responsible blood vessels(30 days (±7 days), 6 months (±60 days) and 12 months (±60 days))
- Angiographic success rate(immediately after procedure)
- The success rate of procedure(In-hospital (Maximum 7 days after procedure))
- Non-stroke bleeding(12 months (±60 days))
- Mortality(30 days (±7 days), 6 months (±60 days) and 12 months (±60 days))
- Serious adverse events and adverse events(12 months (±60 days))
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine NeoplasmsAdvanced Neuroendocrine NeoplasmNCT06398444Sinotau Pharmaceutical Group85
已完成
4 期
Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure InfectionsSkin Diseases, InfectiousNCT00711802Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)396
已完成
不适用
Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent RestenosisCoronary RestenosisNCT02944890ZhuHai Cardionovum Medical Device Co., Ltd.242
终止
不适用
Peri-orbital and Peri-oral Wrinkle Reduction TrialPeri-orbital WrinklesPeri-oral WrinklesNCT01981252Ulthera, Inc90
已完成
不适用
Drug-Eluting Balloon in Arteriovenous GraftAngioplastyDialysisKidney Failure, ChronicNCT03388892National Taiwan University Hospital Hsin-Chu Branch44